By Josée Rose
Teva Pharmaceutical Industries swung to a fourth-quarter loss on lower revenue and an operating loss.
Shares fell about 2.5% in premarket trading to $20.99.
The company swung to a fourth-quarter loss of $217 million, or 19 cents a share, compared with net income of $461 million, or 41 cents a share, a year earlier. Adjusted earnings were 71 cents a share compared with $1 a year earlier.
Revenue fell to $4.23 billion from $4.46 billion a year earlier. The company noted the exchange rate hurt overall revenue by $8 million in the quarter.
Analysts polled by Factset expected an adjusted profit of 71 cents a share and revenue of $4.15 billion.
Teva said its fourth-quarter operating loss was $29 million, compared to an operating income of $755 million a year earlier.
Teva said its generics business continued growing across the globe.
For 2025, the company expects adjusted earnings of $2.35 to $2.65 a share and revenue between $16.8 billion and $17.4 billion
Write to Josée Rose at josee.rose@wsj.com
(END) Dow Jones Newswires
January 29, 2025 08:41 ET (13:41 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。